Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease
Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Oceania. The aim of this trial is to investigate the efficacy of
activated recombinant human factor VII and standard treatment compared with standard
haemostatic replacement therapy in cardiopulmonary bypass (CPB) surgery for paediatric
congenital heart disease.